Pfizer Financial News

Kotak Alternate Asset Managers on Wednesday announced a Rs 1,050-crore investment in Tirupati Medicare, which will support the pharma company's expansion efforts. The investment also gives a complete exit to Affirma Capital, which had invested in the company earlier, according to a statement. The 2005-founded Tirupati is the largest players in the nutraceutical contract manufacturing space, serving a marquee customer base, including Herbalife, Glanbia, Abbott, Torrent, Dr Reddy's, and Pfizer, among others, Kotak Alternate Asset Managers Managing Director Eshwar Karra said.

Subscribe to enjoy similar stories. The White House on Thursday launched its drug-pricing website, dubbed TrumpRx, the culmination of efforts by the administration to bring down pharmaceutical costs for some consumers.

Subscribe to enjoy similar stories. Pfizer in 2019 sold $20 billion of drugs in the U.S. Its federal tax bill? Zero.

Subscribe to enjoy similar stories. Pfizer had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Subscribe to enjoy similar stories. For Pfizer Inc., the strategy has been “go big, or go home". When the covid-19 pandemic first hit, Pfizer’s big bet on its partnership with BioNTech SE hit a home run.

Pfizer zoomed 8.6% to a high of Rs 4,448.35 on the BSE today after the company on Friday announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals. This agreement is regarding the sales and marketing of two brands of the company (Pfizer), Ativan and Pacitane.

Pfizer chairman and CEO Albert Bourla breaks down the companys revenue on The Claman Countdown.

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

«There is a strong support at 23,460 which happens to be the previous swing low, so that is the stop loss in the long positions of the Nifty,» says Vinay Rajani, HDFC Securities. Like Ansh was just highlighting that both the benchmark indices are trading in quite a narrow range and it is more of a short covering led rally that what we are witnessing. Help us with your take on the benchmark indices and where do you see the index headed. Vinay Rajani: So, yes, it is trading within the range of yesterday's move and recovery is there and sector-specific and stock-specific some good moves can be seen on the upside also. So, there is a stock-specific market. Nifty has risen by 110 points, but this can be considered as a pullback only. But however, the froth has gone out and many stocks have started performing, in fact, they are making highs of the recent swings. So, as a trader I would suggest that try to come out with stocks which can outperform this market because as far as benchmark indices are concerned, they are likely to remain in the range or consolidate.

Pfizer and Moderna, saw significant declines following the announcement of Robert F. Kennedy Jr. as President-elect Donald Trump’s pick for Secretary of Health and Human Services. Kennedy, a prominent figure in the anti-vaccine movement, has long propagated controversial views and conspiracy theories about vaccines, which could affect the future of public health policies.

Subscribe to enjoy similar stories. When the world’s most-followed investor doesn’t feel comfortable investing, should the rest of us be worried? Warren Buffett, who has quipped that his favorite holding period for a stock is “forever," continues to have substantial money at work in American companies. But he has never taken this much off the table either—a whopping $325 billion in cash and equivalents, mostly in the form of Treasury bills.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year

Subscribe to enjoy similar stories. Pfizer punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results. The pharmaceutical company raised its revenue outlook for the year to between $61 billion to $64 billion, up from $59.5 billion to $62.5 billion previously.

Subscribe to enjoy similar stories. When former executives team up with an activist investor to “help" a struggling company, it is often bad news for the current chief executive. That is one implication behind activist investor Starboard Value’s $1 billion stake and its push to make changes at Pfizer, which The Wall Street Journal reported has support from former Pfizer Chief Executive Ian Read and former Chief Financial Officer Frank D’Amelio.

U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. The Food and Drug Administration cleared updated shots made by Novavax on Friday

Updated COVID-19 vaccines are on their way

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

About half the U.S. state attorneys general have traveled to France for an event cosponsored by a group largely funded by companies

Pfizer now expects 2024 earnings to wind up well above analyst expectations after starting the year with a forecast that disappointed Wall Street

More companies are rethinking the internet browser, the decades-old desktop application that carries an increasingly heavy enterprise workload. Designed and built originally for consumers, browsers can now connect to an array of workplace applications, from customer relationship management software to videoconferencing.

Federal health officials are strengthening their endorsement of RSV vaccinations for people 75 and older